CRISPR and Gene Editing Therapies: Current Applications in Treating Inherited Disorders
DOI:
https://doi.org/10.70749/ijbr.v3i8.1980Keywords:
CRISPR, gene editing, inherited disorders, public awareness, patient attitudes, genetic therapy, safety perception, education level, demographic analysis, SPSSAbstract
The purpose of the research was to investigate people's perceptions of CRISPR gene editing as a treatment for hereditary illnesses and the factors that shape such perceptions. It also looked at whether age, gender, and education level as well as safety concerns affect their willingness to accept such treatments. The sample used in this study was 250 and they were all patients; moreover, the general population also acted as participants. It was a study conducted between February and June, 2025 in Punjab, Pakistan. The answers were given according to the background, knowledge on CRISPR, and perception of the participants by means of a questionnaire. The SPSS software was used to analyze the data. It was found out that the more a person knew about the CRISPR, the greater the probability to adopt this method. The other factors that made a significant contribution to the willingness of the individuals to use CRISPR were a belief in its safeness and the level of education. Men and younger population were more predisposed to using CRISPR as compared to the older population and the female population. Income did not have much influence on their opinion. It means that raising awareness of people via teaching them about CRISPR is one of the methods that can be used to reduce the lack of acceptance. In the study, it is shown that awareness and trust make a very pivotal role in the uptake of new medical technologies. In the future we will be able to learn even more when additional research is conducted on larger and more diverse samples of people. Meanwhile, the findings of the current investigation can yield beneficial recommendations to physicians, scientists, and policymakers about a discussion with people about CRISPR and develop a safe intervention.
Downloads
References
1. Abdelnour, S.A., et al., The potential of CRISPR/Cas9 gene editing as a treatment strategy for inherited diseases. Frontiers in cell and developmental biology, 2021. 9: p. 699597.
https://doi.org/10.3389/fcell.2021.699597
2. Pacesa, M., O. Pelea, and M. Jinek, Past, present, and future of CRISPR genome editing technologies. Cell, 2024. 187(5): p. 1076-1100.
https://doi.org/10.1016/j.cell.2024.01.042
3. Pandey, V.K., et al., Application of CRISPR/Cas9 genome editing in genetic disorders: a systematic review up to date. J Genet Syndr Gene Ther, 2017. 8(2): p. 1-10.
https://doi.org/10.4172/2157-7412.1000321
4. Lu, X., et al., Applications and research advances in the delivery of CRISPR/Cas9 systems for the treatment of inherited diseases. International journal of molecular sciences, 2023. 24(17): p. 13202.
https://doi.org/10.3390/ijms241713202
5. Wu, S.-S., et al., Advances in CRISPR/Cas-based gene therapy in human genetic diseases. Theranostics, 2020. 10(10): p. 4374.
https://doi.org/10.7150/thno.43360
6. Carvalho, C., et al., Gene therapy for inherited retinal diseases: Exploiting new tools in genome editing and nanotechnology. Frontiers in Ophthalmology, 2023. 3: p. 1270561.
https://doi.org/10.3389/fopht.2023.1270561
7. Liu, W., et al., Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precision clinical medicine, 2021. 4(3): p. 179-191.
https://doi.org/10.1093/pcmedi/pbab014
8. Kan, M.J. and J.A. Doudna, Treatment of genetic diseases with CRISPR genome editing. Jama, 2022. 328(10): p. 980-981.
https://doi.org/10.1001/jama.2022.13468
9. Xu, X., et al., Delivery of CRISPR/Cas9 for therapeutic genome editing. The journal of gene medicine, 2019. 21(7): p. e3107.
https://doi.org/10.1002/jgm.3107
10. Alagoz, M. and N. Kherad, Advance genome editing technologies in the treatment of human diseases: CRISPR therapy. International journal of molecular medicine, 2020. 46(2): p. 521-534.
https://doi.org/10.3892/ijmm.2020.4609
11. Huang, C., Q. Li, and J. Li, Site-specific genome editing in treatment of inherited diseases: possibility, progress, and perspectives. Medical Review, 2022. 2(5): p. 471-500.
https://doi.org/10.1515/mr-2022-0029
12. Matuszek, Z., et al., Current trends in gene therapy to treat inherited disorders of the brain. Molecular Therapy, 2025. 33(5): p. 1988-2014.
13. Doudna, J.A., The promise and challenge of therapeutic genome editing. Nature, 2020. 578(7794): p. 229-236.
14. Hernández-Juárez, J., G. Rodríguez-Uribe, and S. Borooah, Toward the treatment of inherited diseases of the retina using CRISPR-based gene editing. Frontiers in Medicine, 2021. 8: p. 698521.
https://doi.org/10.3389/fmed.2021.698521
15. Jacinto, F.V., W. Link, and B.I. Ferreira, CRISPR/Cas9?mediated genome editing: From basic research to translational medicine. Journal of cellular and molecular medicine, 2020. 24(7): p. 3766-3778.
16. Chien, Y., et al., Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: Applications, challenges, and emerging opportunities. Journal of Nanobiotechnology, 2022. 20(1): p. 511.
https://doi.org/10.1186/s12951-022-01717-x
17. Farooq, R., et al., CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss. Journal of Applied Genetics, 2020. 61(1): p. 51-65.
18. Sundaresan, Y., et al., Therapeutic applications of CRISPR/Cas9 gene editing technology for the treatment of ocular diseases. The FEBS journal, 2023. 290(22): p. 5248-5269.
https://doi.org/10.1111/febs.16771
19. Pellagatti, A., et al., Application of CRISPR/Cas9 genome editing to the study and treatment of disease. Archives of toxicology, 2015. 89(7): p. 1023-1034.
20. Guan, L., et al., CRISPR-Cas9-mediated gene therapy in neurological disorders. Molecular Neurobiology, 2022. 59(2): p. 968-982.
https://doi.org/10.1007/s12035-021-02638-w
21. Christensen, C.L. and F.Y. Choy, A prospective treatment option for lysosomal storage diseases: CRISPR/Cas9 gene editing technology for mutation correction in induced pluripotent stem cells. Diseases, 2017. 5(1): p. 6.
22. Kansal, R., The CRISPR-Cas system and clinical applications of CRISPR-based gene editing in hematology with a focus on inherited germline predisposition to hematologic malignancies. Genes, 2024. 15(7): p. 863.
https://doi.org/10.3390/genes15070863
23. Yilmaz, B.S., et al., Gene therapy for inherited metabolic diseases. Journal of Mother and Child, 2020. 24(2): p. 53.
24. Cetin, B., et al., Gene and cell therapy of human genetic diseases: Recent advances and future directions. Journal of Cellular and Molecular Medicine, 2024. 28(17): p. e70056.
https://doi.org/10.1111/jcmm.70056
25. Papasavva, P., M. Kleanthous, and C.W. Lederer, Rare opportunities: CRISPR/Cas-based therapy development for rare genetic diseases. Molecular diagnosis & therapy, 2019. 23(2): p. 201-222.
26. Redman, M., et al., What is CRISPR/Cas9? Archives of Disease in Childhood-Education and Practice, 2016. 101(4): p. 213-215.
https://doi.org/10.1136/archdischild-2016-310459
27. Sharma, G., et al., CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases. Molecular Therapy, 2021. 29(2): p. 571-586.
28. De Masi, C., et al., Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery. Human genomics, 2020. 14(1): p. 25.
https://doi.org/10.1186/s40246-020-00276-2
29. Kang, X.J., et al., Addressing challenges in the clinical applications associated with CRISPR/Cas9 technology and ethical questions to prevent its misuse. Protein & cell, 2017. 8(11): p. 791-795.
30. Torella, L., et al., Gene editing in liver diseases. FEBS letters, 2024. 598(19): p. 2348-2371.
31. Suh, S., et al., Precision genome editing in the eye. Proceedings of the National Academy of Sciences, 2022. 119(39): p. e2210104119.
https://doi.org/10.1073/pnas.2210104119
32. Singh, K., et al., Precision genome editing techniques in gene therapy: current state and future prospects. Current Gene Therapy, 2024. 24(5): p. 377-394.
https://doi.org/10.2174/0115dcs9VQfXYjs99cSWhuNKKKeFqVwerm2
33. Khoshandam, M., et al., CRISPR challenges in clinical developments. Progress in Molecular Biology and Translational Science, 2025. 210: p. 263-279.
https://doi.org/10.1016/bs.pmbts.2024.08.001
34. Lotfi, M., et al., Application of CRISPR?Cas9 technology in diabetes research. Diabetic Medicine, 2024. 41(1): p. e15240.
https://doi.org/10.1111/dme.15240
35. Brunetti-Pierri, N., Gene therapy and gene editing, in Handbook of Clinical Adult Genetics and Genomics. 2020, Elsevier. p. 463-477.
https://doi.org/10.1016/b978-0-12-817344-2.00030-7
36. Mirgayazova, R., et al., Therapeutic editing of the TP53 gene: is CRISPR/Cas9 an option? Genes, 2020. 11(6): p. 704.
https://doi.org/10.3390/genes11060704
37. Braga, L.A.M., C.G. Conte Filho, and F.B. Mota, Future of genetic therapies for rare genetic diseases: what to expect for the next 15 years? Therapeutic advances in rare disease, 2022. 3: p. 26330040221100840.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
